United BioSource Scientist Leads Development of New Guidelines for Drug Reimbursement by German Government

Wednesday, February 20, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

BETHESDA, Md., Feb. 19 United BioSource Corporation's(UBC) director of global health economics has just delivered to the Germangovernment one of the most significant revisions of drug policy produced inEurope in more than a decade.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070910/NEM007LOGO )

The 70-page report, commissioned last year by Germany's Institute forQuality and Efficiency In Healthcare (IQWiG), will be used by the Germangovernment to evaluate drugs and devices and to set prices and reimbursementlevels for those products. The document is expected to be widely influentialboth inside and outside of Germany, the third largest pharmaceutical market inthe world.

The director and main author of the report, Jaime Caro, MD, Senior VicePresident of UBC, was selected by the German government to head the eight-member international panel because of his recognized authority in the designand implementation of cutting-edge modeling and analytic techniques for healthtechnology assessments, particularly in determining the value and safety ofmedical products.

According to Dr. Caro, "It was an immense honor to lead such adistinguished panel in developing pioneering methods for economic evaluation.These methods will have a strong influence on the efforts of society tocontrol health care costs. I am very glad that with my team of experiencedprofessionals at UBC, we can work towards improving health outcomes."

Made public in Berlin on January 24, 2008 by IQWiG, the findings andrecommendations of the expert panel, if accepted, will directly impact thepricing and reimbursement of pharmaceuticals, biologicals and medical devicesin Germany, which has the largest population of any EU nation.

Dr. Caro recommends that companies with marketed products and products indevelopment set up a process to assess where the pharmaceuticals fall underthe new methods and "be prepared to defend their position, understanding thatthey might need additional data or other strategies."

The report is titled Methods for Assessment of the Relation of Benefits toCosts in the German Statutory Health Care System.

United BioSource Corporation (UBC) is a global pharmaceutical servicesorganization that helps emerging and established life science companiesdevelop and commercialize medical products. UBC specializes in offering newand innovative ways to study drugs and devices by offering expertise inscience, strategy and execution.

UBC is headquartered in Bethesda, Maryland, with offices in the UnitedStates, Canada, Western Europe (including Cologne, Germany), Eastern Europeand South America. For more information, visit www.unitedbiosource.com or call866-458-1096.

CONTACT: Tess Drahzal, +1 (240) 644-0420, info@unitedbiosource.comAvailable Topic Expert(s): For information on the listed expert(s), clickappropriate link.Jaime Caro, MDhttp://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=73597

SOURCE United BioSource Corporation

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store